Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
APLM
SellHot AirApollomics, Inc. · Healthcare · United States · $77M · Avg Vol: $576K/d
28
StockRankGet insider-trade alerts
Q
36
V
25
M
55
P/E (TTM)
—
ROE
-1305.4%
D/E
—
Dividend %
—
COMPANY DESCRIPTION
Apollomics, Inc. is a biopharmaceutical company focused on developing oncology therapies for difficult-to-treat cancers. It leverages a clinical-stage pipeline that utilizes both internal R&D and strategic collaborations to address unmet medical needs in global oncology markets.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 8.5M | — | 8.8M |
| EPS | -1.18 | -83.15 | -71.69 | -20.11 | -5.09 | — | -7.57 |
| Shares | — | 2.9M | 2.9M | 2.9M | 2.1M | -25.9% | 2.9M |
| Debt | — | 1.0M | 4.7M | 1.0M | 0.6M | -13.4% | 0.6M |
| Equity | — | -448.1M | 41.2M | 4.9M | -3.2M | -88.2% | — |
| Op CF | — | -42.8M | -43.2M | -28.7M | -10.4M | — | -10.4M |
| Inv CF | — | 29.1M | 21.4M | 6.0M | 0.2M | — | — |
| Fin CF | — | -0.3M | 21.2M | 0.5M | 3.7M | — | — |
Loading 1Y...
PRICE (1Y)+37.5%
SMA 50SMA 200
Close
$23.86
RSI (14)
51.1
52W High
$42.12
From 52W High
0.6%
SCORE BREAKDOWN
Quality
36
ROIC
-2801.8%0.2
ROE
-1305.4%25.0
GP/Assets
131.7%99.1
Op. Margin
431.9%99.6
FCF/Assets
-146.1%1.0
Piotroski
438.9
Int. Cover
-50.0x5.9
D/E Ratio
—N/A
Current Ratio
0.96x10.2
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-6.5x25.0
P/FCF
—N/A
P/B
-18.5x25.0
P/S
9.0x27.8
Div Yield
—N/A
Momentum
55
52W High %
57%31.5
RS 6M
4%70.8
SMA 50/200
1.15x83.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+91%71.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$77M
P/E (Forward)
-42.3x
Gross Margin
100.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of APLM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| APLM | Apollomics, Inc.(you) | $77M | 28 | Sell |
| RNXT | RenovoRx, Inc. | $75M | 26 | Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 26 | Sell |
| INMB | INmune Bio Inc. | $65M | 31 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 23 | Sell |
| MNOV | MediciNova, Inc. | $71M | 23 | Sell |
| SEER | Seer, Inc. | $110M | 28 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%